INCY Incyte Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: INCY

Price (delayed)

$55.43

Market cap

$12.42B

P/E Ratio

29.33

Dividend/share

N/A

EPS

$1.89

Enterprise value

$9.23B

Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware. The company was founded in Palo Alto, California in 1991 and went public in 1993. Incyte has one drug, ...

Highlights
INCY's P/E is 33% below its 5-year quarterly average of 43.4 and 32% below its last 4 quarters average of 42.6
INCY's equity is up by 17% year-on-year and by 4% since the previous quarter
INCY's EPS has shrunk by 52% YoY but it is up by 15% QoQ
INCY's net income has dropped by 51% year-on-year but it is up by 16% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.incyte.com/
Peers: AMGN LGND LLY PFE

Key stats

What are the main financial stats of INCY
Market
Shares outstanding
224.11M
Market cap
$12.42B
Enterprise value
$9.23B
Valuations
Price to earnings (P/E)
29.33
Price to book (P/B)
2.52
Price to sales (P/S)
3.44
EV/EBIT
14.27
EV/EBITDA
12.72
EV/Sales
2.56
Earnings
Revenue
$3.61B
EBIT
$646.29M
EBITDA
$725.4M
Free cash flow
$580.93M
Per share
EPS
$1.89
Free cash flow per share
$2.59
Book value per share
$22.01
Revenue per share
$16.11
TBVPS
$27.24
Balance sheet
Total assets
$6.39B
Total liabilities
$1.46B
Debt
$31.92M
Equity
$4.93B
Working capital
$3.28B
Liquidity
Debt to equity
0.01
Current ratio
3.91
Quick ratio
3.71
Net debt/EBITDA
-4.41
Margins
EBITDA margin
20.1%
Gross margin
93.2%
Net margin
11.8%
Operating margin
13.9%
Efficiency
Return on assets
7%
Return on equity
9.2%
Return on invested capital
38.8%
Return on capital employed
12.3%
Return on sales
17.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

INCY stock price

How has the Incyte stock price performed over time
Intraday
1.11%
1 week
3.82%
1 month
1.58%
1 year
-32.84%
YTD
-30.99%
QTD
-4.05%

Financial performance

How have Incyte's revenue and profit performed over time
Revenue
$3.61B
Gross profit
$3.36B
Operating income
$503.35M
Net income
$424.98M
Gross margin
93.2%
Net margin
11.8%
The net margin has dropped by 55% year-on-year but it is up by 13% since the previous quarter
INCY's net income has dropped by 51% year-on-year but it is up by 16% since the previous quarter
INCY's operating margin is down by 25% year-on-year but it is up by 14% since the previous quarter
Incyte's operating income has decreased by 19% YoY but it has increased by 18% from the previous quarter

Growth

What is Incyte's growth rate over time

Valuation

What is Incyte stock price valuation
INCY P/E details
P/E
29.33
P/B
2.52
P/S
3.44
EV/EBIT
14.27
EV/EBITDA
12.72
EV/Sales
2.56
INCY's EPS has shrunk by 52% YoY but it is up by 15% QoQ
INCY's P/E is 33% below its 5-year quarterly average of 43.4 and 32% below its last 4 quarters average of 42.6
The stock's price to book (P/B) is 58% less than its 5-year quarterly average of 5.9 and 25% less than its last 4 quarters average of 3.3
INCY's equity is up by 17% year-on-year and by 4% since the previous quarter
INCY's P/S is 48% below its 5-year quarterly average of 6.5 and 23% below its last 4 quarters average of 4.4
Incyte's revenue has increased by 8% YoY and by 2.7% from the previous quarter

Efficiency

How efficient is Incyte business performance
INCY's return on assets has dropped by 58% year-on-year but it is up by 11% since the previous quarter
The ROE has plunged by 58% YoY but it has grown by 12% from the previous quarter
The ROIC has increased by 13% YoY and by 11% from the previous quarter
INCY's ROS is up by 12% QoQ and by 4.1% YoY

Dividends

What is INCY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INCY.

Financial health

How did Incyte financials performed over time
Incyte's total assets has increased by 16% YoY and by 2.9% from the previous quarter
INCY's total liabilities is up by 13% year-on-year
The debt is 99% smaller than the equity
INCY's equity is up by 17% year-on-year and by 4% since the previous quarter
The debt is down by 5% year-on-year and by 2.2% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.